[CTLT] Catalent, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 2.96 B

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 26.9 Change: 0.56 (2.13%)
Ext. hours: Change: 0 (0%)

chart CTLT

Refresh chart

Strongest Trends Summary For CTLT

CTLT is in the long-term up 70% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through three segments: Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development, and manufacturing of oral dose forms for prescription and consumer health products. This segment?s oral dose forms include soft gel, modified release technologies, and immediate release solid oral products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development & Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also offers analytical chemical and cell-based testing and scient

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding124.71 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -14.05% Sales Growth - Q/Q-2.02% P/E
P/E To EPS Growth P/S1.61 P/BV6.33 Price/Cash Per Share
Price/Free Cash Flow53.01 ROA2.88% ROE18.13% ROI3.43%
Current Ratio1.79 Quick Ratio1.4 Long Term Debt/Equity6.45 Debt Ratio0.77
Gross Margin33.9% Operating Margin14.77% Net Profit Margin4.66% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities209 M Cash From Investing Activities-240.3 M Cash From Operating Activities94.7 M Gross Profit152.2 M
Net Profit31.5 M Operating Profit65.8 M Total Assets2.97 B Total Current Assets653.1 M
Total Current Liabilities365.4 M Total Debt1.88 B Total Liabilities2.51 B Total Revenue446.6 M
Technical Data
High 52 week46.34 Low 52 week29.84 Last close45.18 Last change0.38%
RSI72.59 Average true range1.41 Beta1.09 Volume419.58 K
Simple moving average 20 days7.41% Simple moving average 50 days7.09% Simple moving average 200 days12.72%
Performance Data
Performance Week2.59% Performance Month11.47% Performance Quart23.81% Performance Half15.52%
Performance Year9.34% Performance Year-to-date44.9% Volatility daily2.94% Volatility weekly6.57%
Volatility monthly13.46% Volatility yearly46.63% Relative Volume271.85% Average Volume828.46 K
New High New Low


2019-06-10 08:06:38 | See what the IHS Markit Score report has to say about Catalent Inc.

2019-05-30 16:15:00 | Catalent, Inc. to Present at the Jefferies Healthcare Conference

2019-05-30 08:04:59 | See what the IHS Markit Score report has to say about Catalent Inc.

2019-05-28 08:05:07 | See what the IHS Markit Score report has to say about Catalent Inc.

2019-05-21 08:52:12 | Catalent Acquires Gene Therapy Leader Paragon Bioservices

2019-05-20 08:30:00 | Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion

2019-05-09 14:20:11 | Catalent Pharma Solutions, Inc. -- Moody's downgrades Catalent's senior secured rating to Ba3, affirms B1 CFR rating; the outlook remains stable

2019-05-08 08:31:01 | Edited Transcript of CTLT earnings conference call or presentation 7-May-19 12:15pm GMT

2019-05-07 14:23:34 | Catalent Inc CTLT Q3 2019 Earnings Call Transcript

2019-05-07 08:55:12 | Catalent CTLT Surpasses Q3 Earnings Estimates

2019-05-07 08:03:34 | See what the IHS Markit Score report has to say about Catalent Inc.

2019-05-07 07:45:36 | Catalent: Fiscal 3Q Earnings Snapshot

2019-05-07 07:30:00 | Catalent, Inc. Reports Third Quarter Fiscal 2019 Results

2019-04-30 10:32:02 | Catalent CTLT Earnings Expected to Grow: What to Know Ahead of Next Week's Release

2019-04-24 10:52:31 | Did Hedge Funds Drop The Ball On Catalent Inc CTLT ?

2019-04-17 16:05:16 | Catalent Pharma Solutions, Inc. -- Moody's announces completion of a periodic review of ratings of Catalent Pharma Solutions, Inc.

2019-04-17 11:37:08 | Catalent Pharma Solutions, Inc. -- Moody's: Catalent's acquisition of Paragon will increase leverage, a credit negative

2019-04-15 15:33:27 | Catalent seeks slice of gene therapy market with Paragon buy

2019-04-15 09:53:00 | Catalent to Buy Paragon Bioservices for $1.2 Billion

2019-04-15 09:27:11 | Catalent Agrees To Buy Gene Therapy-Focused CDMO Paragon Services For $1.2B

2019-04-15 08:12:08 | Stocks making the biggest moves premarket: Goldman Sachs, CVS, Best Buy, Facebook & more

2019-04-15 07:15:00 | Catalent to acquire Paragon Bioservices for $1.2 billion in cash

2019-04-15 07:13:41 | Catalent to buy Paragon Bioservices for $1.2 bln

2019-04-15 07:02:00 | Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion

2019-04-14 23:17:33 | Catalent to buy Paragon Bioservices for $1.2 billion - WSJ

2019-04-14 19:42:09 | Catalent to buy Paragon Bioservices for $1.2 bln - WSJ

2019-04-14 19:39:19 | Catalent to buy Paragon Bioservices for $1.2 bln -WSJ

2019-04-11 07:13:13 | Update: Catalent NYSE:CTLT Stock Gained 34% In The Last Three Years

2019-04-09 16:15:00 | Catalent, Inc. Announces Third Quarter Fiscal Year 2019 Earnings Conference Webcast

2019-04-09 10:45:48 | See what the IHS Markit Score report has to say about Catalent Inc.

2019-04-03 09:30:01 | CTLT or ORINY: Which Is the Better Value Stock Right Now?

2019-04-03 07:30:00 | Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience

2019-03-26 08:21:56 | See what the IHS Markit Score report has to say about Catalent Inc.

2019-03-15 09:30:01 | CTLT or NBIX: Which Is the Better Value Stock Right Now?

2019-03-07 06:07:06 | Is Catalent, Inc.’s NYSE:CTLT Balance Sheet A Threat To Its Future?

2019-03-06 16:15:00 | Catalent, Inc. to Present at the Barclays Global Healthcare Conference

2019-03-04 23:40:04 | Champions Oncology CSBR Q3 Earnings: What's in Store?

2019-02-27 09:57:02 | The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris

2019-02-26 08:55:01 | 4 Drug Stocks to Buy Despite Price Hearing Woes

2019-02-15 08:16:01 | Will Catalent Continue to Surge Higher?

2019-02-13 07:00:00 | Catalent Names Alessandro Maselli President and Chief Operating Officer

2019-02-12 09:30:02 | CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?

2019-02-08 08:07:11 | See what the IHS Markit Score report has to say about Catalent Inc.

2019-02-05 14:50:57 | Edited Transcript of CTLT earnings conference call or presentation 5-Feb-19 1:15pm GMT

2019-02-05 12:55:19 | Catalent Inc CTLT Q2 2019 Earnings Conference Call Transcript

2019-02-05 08:55:01 | Catalent CTLT Beats Q2 Earnings and Revenue Estimates

2019-02-05 07:52:35 | Catalent: Fiscal 2Q Earnings Snapshot

2019-02-05 07:30:00 | Catalent, Inc. Reports Second Quarter Fiscal 2019 Results

2019-01-29 10:31:03 | Analysts Estimate Catalent CTLT to Report a Decline in Earnings: What to Look Out for

2019-01-29 08:03:11 | See what the IHS Markit Score report has to say about Catalent Inc.